Cronos Group

GrowCo Capacity And Global Markets Will Unlock Potential

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

30 Apr 25

Updated

04 Sep 25

Views

103

n/a

AnalystConsensusTarget's Fair Value

n/a

61.0%

12.9%

61.0%

12.9%

You can edit this narrative until Sep 5 10:25 AM. Then, changes will post as Updates.

Author's Valuation

CA$3.9510.9% overvalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on 04 Sep 25

Fair value Increased 8.72%

The Consensus Analyst Price Target for Cronos Group has increased to CA$3.95, primarily reflecting a notable rise in the company's Future P/E multiple despite stable revenue growth expectations. What's in the News President Trump is considering reclassifying marijuana as a less dangerous drug, which could ease restrictions and benefit cannabis companies such as Cronos Group (The Wall Street Journal).

AnalystConsensusTarget Fair Value

CA$3.95

10.9% overvalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

5.55%

Pharma revenue growth rate

0.62%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.12%

Calculation

US$45.54m

Earnings '28

28.72x

PE Ratio '28

US$1.31b

Market Cap '28

US$1.31b

Market Cap '28

384.88m

No. shares '28

US$3.40

Share Price '28

US$3.40 Share Price '28

Discounted to 2025 @ 5.97% p.a.

US$2.86

Fair Value '25

US$2.86 Fair Value '25

Converted to CAD @ 1.3799 USD/CAD Exchange Rate

CA$3.95

Fair Value '25